← back to search

Vijayakrishna K. Gadi

Illinois College · US
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies, and Lung Cancer Treatments and Mutations.
h-index
31
citations
3,430
works
187
NIH funding
primary concept
Medicine
email

Recent publications

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Journal of Clinical Oncology 2024cited by 36position: middledoi
Associations of Multiparametric Breast MRI Features, Tumor-Infiltrating Lymphocytes, and Immune Gene Signature Scores Following a Single Dose of Trastuzumab in HER2-Positive Early-Stage Breast Cancer
Cancers 2023cited by 6position: lastdoi
Clinical outcomes in patients with metastatic non-small cell lung cancer and head and neck squamous cell cancer treated with immune checkpoint inhibitors according to COVID-19 vaccination status.
Journal of Clinical Oncology 2023cited by 3position: middledoi
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
npj Breast Cancer 2022cited by 15position: middledoi
Preoperative Systemic Therapy for Breast Cancer
Surgical Clinics of North America 2022cited by 14position: lastdoi
Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer
Annals of Surgical Oncology 2022cited by 14position: lastdoi
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Journal of Clinical Oncology 2021cited by 138position: middledoi
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
Breast Cancer Research and Treatment 2021cited by 35position: middledoi
Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy
Advances in Nutrition 2021cited by 35position: middledoi
Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)
Cancer Research 2020cited by 26position: middledoi
The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines
Vaccines 2020cited by 20position: lastdoi
Microtransplantation in older patients with <scp>AML</scp>: A pilot study of safety, efficacy and immunologic effects
American Journal of Hematology 2020cited by 13position: middledoi
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Cancer Discovery 2017cited by 944position: middledoi
Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies
Scientific Reports 2017cited by 2position: middledoi
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
EJNMMI Research 2012cited by 33position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mary Pasquinelli · University of Illinois Chicago1 papers (2023–2023)Elisabeth Mahen · University of Minnesota, Twin Cities1 papers (2017–2017)Li Liu · University of Illinois Chicago1 papers (2023–2023)Donna Prunkard · Seattle University1 papers (2017–2017)Brenda F. Kurland · GlaxoSmithKline (United States)1 papers (2012–2012)Frank Weinberg · University of Illinois Chicago1 papers (2023–2023)Lawrence Feldman · University of Illinois Chicago1 papers (2023–2023)Bonny Chau · New York Medical College1 papers (2023–2023)Jay Shendure · Howard Hughes Medical Institute1 papers (2017–2017)Choli Lee · University of Washington1 papers (2017–2017) · 1 papers (2023–2023)Abhigna Kodali · Tufts University1 papers (2022–2022)Kimberly H. Allison · Stanford Medicine1 papers (2012–2012)Karam Khaddour · University of Illinois Chicago1 papers (2023–2023)Jeffrey A. Bilmes · University of Washington1 papers (2017–2017)Xu Ziqiao · University of Illinois Chicago1 papers (2023–2023)Jie Liu · University of Michigan–Ann Arbor1 papers (2017–2017)Xiaoyu Chai · Nanjing Tech University1 papers (2012–2012)Ryan Huu-Tuan Nguyen · University of Illinois Chicago1 papers (2023–2023)Michael O. Dorschner · University of Washington Medical Center1 papers (2017–2017)